ArticleKidney medicine2026
Association Between Blood Cobalt Levels and Arteriovenous Fistula Dysfunction in Patients Undergoing Maintenance Hemodialysis: A Multicenter Observational Study.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Prior studies have suggested that increased cobalt ion concentrations in circulation provoke inflammation in endothelial cells, disrupting vascular function. In patients undergoing maintenance hemodialysis (MHD), elevated cobalt may result from various factors. Given the critical role of arteriovenous fistulas (AVFs) in the survival of MHD patients, we aimed to investigate the relationship between cobalt levels and AVF dysfunction. Study Design: Multicenter, observational cohort study. Setting & Study Populations: A total of 518 patients undergoing maintenance hemodialysis at 3 medical centers. Exposures: Blood samples were collected before dialysis, and whole-blood cobalt levels were determined using inductively coupled plasma mass spectrometry. Outcomes: Blood cobalt concentrations were measured at baseline. Participants were monitored for AVF dysfunction, defined by a blood flow reduction to ≤200 mL/min during dialysis, and followed up to 2 years. Analytical Approach: Patients were divided into groups based on the occurrence of AVF dysfunction and analyzed using multivariable Cox regression, Kaplan-Meier curves, log-rank tests, restricted cubic spline analysis, and stratified analysis. Results: Of the 518 patients, 126 (24.3%) experienced AVF dysfunction within a median 16-month follow-up. Patients with AVF dysfunction exhibited significantly higher blood cobalt concentrations than did those without AVF dysfunction. The highest AVF dysfunction rate was observed in patients in the upper cobalt quartile ( Limitations: We only assessed the baseline cobalt levels at enrollment and did not perform serial measurements; we could not determine whether factors influencing trace element intake or absorption (eg, dietary habits or lifestyle) might have introduced temporal fluctuations in cobalt levels during follow-up, potentially influencing the results. Conclusions: Elevated blood cobalt levels were independently associated with an increased risk of AVF dysfunction in patients undergoing MHD. Further research on cobalt metabolism and its effects on AVF functionality to guide clinical interventions is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.